Tramadol Prescription over a 4-Year Period in the USA
Purpose of Review
Deaths associated to tramadol, a synthetic opioid, are rising globally. Herein, we characterize prescription patterns of tramadol relative to other opioids in the USA from 2012 to 2015, by geographic region and physician specialty.
Data on opioid was obtained using Truven Health Analytics MarketScan for the years 2012–2015. Inclusion criteria included subjects living in the USA with ages from 12 to 64 years. Patterns of prescription of tramadol were contrasted with other prescription opioids including hydrocodone, codeine, oxycodone, oxymorphone, methadone, and fentanyl. Between 2012 and 2015, prescriptions for tramadol increased by 22.8%. The absolute rate of prescription varies considerably per region, with tramadol representing nearly 20% of opioid prescriptions in the South, which, in turn, represents nearly 50% of all prescriptions in the USA. Significant differences were seen when comparing prescribers of tramadol with other opioids (p < 0.0001). Tramadol was more frequently prescribed by family practice (40% vs. 32%) and internal medicine physicians (19% vs. 16%). Family medicine, internal medicine, and non-physician prescribers responded by 67.2% of all tramadol prescriptions in 2015. The proportion of patients receiving tramadol from non-physician prescribers increased by 56% between 2012 and 2015 (p < 0.001) IOM.
Tramadol prescriptions rates have continuously increased both nationally and throughout all US regions. Important differences exist among regions and physician specialties. These results may be helpful in the creation of regional policies to monitor reasons for this increase and to avoid excessive use of tramadol.
KeywordsTramadol Opioids Prescription rates Prescription patterns
Compliance with Ethical Standards
Conflict of Interest
Luisa M. Bigal conducted this study as part of a paid internship at Teva Pharmaceuticals. Kristen Bibeau is a full-time employee at Incyte Corporation and was a full-time employee at Teva at the time of data collection. Stephanie Dunbar is a full-time employee at Teva.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
- 3.Groenewald CB, Rabbitts JA, Gebert JT, Palermo TM. Trends in opioid prescriptions among children and adolescents in the United States: a nationally representative study from 1996 to 2012. Pain. 2016;157(5):1021–7. https://doi.org/10.1097/j.pain.0000000000000475.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Chandanwale AS, Sundar S, Latchoumibady K, et al. Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a phase III, 5-day open-label study. J Pain Res. 2014;7:455–63. https://doi.org/10.2147/JPR.S67817.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Administration US-DE. Drug scheduling [cited 2018 08/07/2018]. Available from: https://www.dea.gov/druginfo/ds.shtml
- 18.Board INC. Report of the international narcotics control board for 2012. New York: United Nations; 2013. [cited 2018 08/07/2018]. Available from: http://incb.org/documents/Publications/AnnualReports/AR2012/AR_2012_E.pdf.Google Scholar
- 19.Analytics TH. Market scan studies - abbreviated bibliography 2018 [cited 2018 09/14/2018]. Available from: http://truvenhealth.com/Portals/0/Assets/2017_Truven_Health_MarketScan_Bibliography.pdf.
- 20.DeGrauw X, Thurman D, Xu L, Kancherla V, DeGrauw T. Epidemiology of traumatic brain injury-associated epilepsy and early use of anti-epilepsy drugs: an analysis of insurance claims data, 2004-2014. Epilepsy Res. 2018 Jul 23;146:41–9. https://doi.org/10.1016/j.eplepsyres.2018.07.012. CrossRefPubMedGoogle Scholar
- 23.Analytics TH. The Truven Health MarketScan Databases for health services researchers 2018. Available from: https://truvenhealth.com/portals/0/assets/2017_MarketScan_Databases_Health_Services_Researchers.pdf.
- 28.O’Donnell JK, Gladden RM, Seth P. Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region - United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(34):897–903. https://doi.org/10.15585/mmwr.mm6634a2.CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Health MDo. Patterns of opioid prescribing in Minnesota: 2012 and 2015 [cited 2018 08/17/2018]. Available from: http://www.health.state.mn.us/divs/hpsc/hep/publications/opioidbrief20185.pdf.
- 45.Control CfD. Prescription drug time and dosage limit Laws. 2017 [cited 2018 11/04/2018]. Available from: https://www.cdc.gov/phlp/docs/menu_prescriptionlimits.pdf
- 50.Reinhart M, Scarpati LM, Kirson NY, Patton C, Shak N, Erensen JG. The economic burden of abuse of prescription opioids: a systematic literature review from 2012 to 2017. Appl Health Econ Health Policy. 2018;16(5):609–32. https://doi.org/10.1007/s40258-018-0402-x.CrossRefPubMedPubMedCentralGoogle Scholar